Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J.P. Morgan Roundtable: Financing Challenges, And Opportunities, For Complex Therapies

Executive Summary

Part 1: Scrip spoke with companies working on cell and gene therapies and novel neuroscience platforms – areas difficult to finance in the past, but seeing increasing investor interest – about funding challenges and opportunities in 2019.


Related Content

Kiadis Buying CytoSen Will Combine Natural Killer And T-Cell Immunotherapies
United Neuroscience To Move Forward Alzheimer's Vaccine After Promising Phase IIa
FDA Ups Pressure On Stem Cell Therapy Makers To Follow Product Approval Rules
Early-Stage Cell And Gene Therapy Progress: Updates From Casebia, BlueRock, Athersys, Cynata
Trade War Spreads: Trump Rains On China Biotech Investment Parade
Deal Watch: Gilead Continues To Add To IO Armamentarium In Collaboration With Gadeta
Bayer/Versant Launch New Stem Cell Company With Massive Cash Injection


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts